Industry Update: Biotechnology

IBiotech industry updatendustry Highlights

  • On October 28, 2020, Seagen Inc. (Seattle Genetics) closed on its billion dollar cancer development partnership with Merck Sharp & Dohme Corp. Seagen is eligible to receive progress-dependent milestone payments of up to $2.6 billion from the ladiratuzumab vedotin collaboration.
  • On December 10, 2020, Gilead Sciences, Inc. and MYR GmbH, a German biotechnology company focused on the treatment of the chronic hepatitis delta virus, announced that the companies have entered a definitive agreement pursuant to which Gilead will acquire MYR for approximately $1.7 billion.

Past Industry Updates

More Industry Reports